TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06632314

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enteral feeding
Description: Enteral feeding will be withheld or continued in very low birthweight neonates during packed red blood cell transfusion. Regional cerebral and splanchnic oxygenation will be measured using near-infrared spectroscopy (NIRS) for 48 hours. Cerebral and splanchnic oxygenation parameters, including cerebral regional oxygen saturation (crSO2), splanchnic regional oxygen saturation (srSO2), the ratio of crSO2 to srSO2 (CSOR), cerebral fractionated tissue oxygen saturation (cFTOE) and splanchnic fractionated tissue oxygen saturation (sFTOE) will be measured immediately before PRBCT (baseline) and at the first, sixth, 12th, 24th, and 48th hours after PRBCT using near-infrared spectroscopy.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enteral feeding
Description: Enteral feeding will be withheld or continued in very low birthweight neonates during packed red blood cell transfusion. Regional cerebral and splanchnic oxygenation will be measured using near-infrared spectroscopy (NIRS) for 48 hours. Cerebral and splanchnic oxygenation parameters, including cerebral regional oxygen saturation (crSO2), splanchnic regional oxygen saturation (srSO2), the ratio of crSO2 to srSO2 (CSOR), cerebral fractionated tissue oxygen saturation (cFTOE) and splanchnic fractionated tissue oxygen saturation (sFTOE) will be measured immediately before PRBCT (baseline) and at the first, sixth, 12th, 24th, and 48th hours after PRBCT using near-infrared spectroscopy.
Study: NCT06633146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapies in nature
Description: Therapeutic tasks in nature specifically designed for the study
Study: NCT06633731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biocellulose Mask
Description: Immediately after treatment, a Biocellulose Mask was applied to the subjects global face for 8 to 10 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post Procedure Cream
Description: Immediately after treatment and after Biocellulose Mask removal, the Post-Procedure Cream was applied to the subjects global face. Subjects were instructed to apply to the global face from days 1 - 3 post treatment.
Study: NCT06417008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aumolertinib
Description: 110 mg orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aumolertinib
Description: 110 mg orally once daily.
Study: NCT05182541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided self help
Description: Introduce the knowledge about twins pregnancy, and reduce the pregnant stress, and relief the anxiety and depressor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Problem solving therapy
Description: Based on the steps of problem-solving therapy, nurses guide mothers with mild psychological problems to solve the existing problems through wechat and telephone, 10-15 min each time for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Problem solving therapy
Description: Based on the steps of problem-solving therapy, nurses guide mothers with mild psychological problems to solve the existing problems through wechat and telephone, 10-15 min each time for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face to face PST course
Description: Face to face interviews with nurses with psychological counselors, combined with auxiliary tools, identify patients' problems, set goals for patients, provide different solutions, and let patients choose appropriate ways according to their preferences. Once a week, 1 hour for the first time and 45 min for the rest for 5 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Professional psychological intervention
Description: The mental health physicians and (or) psychological counselors strengthened the intervention and carried out specialized nursing
Study: NCT04974268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific supervised exercise and weight loss program
Description: Intervention group that receives supervised exercise and weight loss program based on individual and group intervention with Mediterranean diet and substitute for a daily meal, manual lymphatic drainage and compression garment if there is more than 600 ml of excess volume in the limb affected.
Study: NCT06633731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gentle Cleanser
Description: Subjects were instructed to wash their face with the Gentle Foaming Cleanser twice daily for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Moisturizer
Description: Subjects were instructed to apply the facial moisturizer twice daily to the global face from day 3 after treatment until next study visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sunscreen
Description: Subjects were instructed to apply the bland sunscreen to the global face once daily in the morning, with re-application with extended sun exposure per FDA guidelines.
Study: NCT06632522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: radiotherapy combined with Camrelizumab and Apatinib
Description: Camrelizumab is administered intravenously (without preventive medication), with a fixed dose of 200mg, with an infusion of 30 min (not less than 20 min and not more than 60 min) every three weeks. Apatinib, 250 mg, taken orally within half an hour after meals, QD, continuously.
Study: NCT05117268

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SDF Application for caries arrest
Description: Intervention will be performed by trained consultants following the recommended protocol for SDF application: (A) Gross debris will be removed from cavity to allow better contact with SDF; (B) Protective coating of petroleum jelly will be applied to surrounding facial skin and lips to prevent chances of temporary tattoo formation; (C) Area to be treated shall be isolated using cotton rolls and saliva ejectors to prevent gingival irritation; (D) Extra caution will be exercised when applying SDF on primary teeth adjacent to permanent teeth to avoid inadvertent black staining; (E) One drop will be used used for the whole appointment. Bent micro-brush is to be used for application time of 1 min is to be used to reduce systemic absorption; (F) Compressed air shall be applied with gentle flow for up to 3 minutes. Entire dentition will be treated with sodium fluoride varnish to prevent caries
Study: NCT05246670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palmidrol
Description: Given PEA PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palmidrol
Description: Given PEA PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT05815147

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified Powdered Beverage
Description: Participants will be asked to take the fortified powdered beverage everyday for 6 weeks.
Study: NCT05117268

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Glass ionomer restoration
Description: The lesions of control group glass ionomer restoration group will be treated according to following clinical protocol: (A) Isolation of treatment area using cotton rolls and saliva ejectors; (B) Carious lesion excavation using high speed handpiece; (C) High viscosity glass ionomer cement mixed following manufacturer's instructions; (D) Cavity will be slightly overfilled using a flat plastic instrument, the occlusal surface will be protected with Vaseline and gloved finger will be used to apply slight pressure for 30s. Postoperative instructions will be clearly explained to each patient caregiver.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hall technique
Description: In Hall technique, correct size preformed metal crown will be selected and shall be placed without caries excavation. The crown will be filled with glass ionomer cement and seated with finger pressure. Local anesthesia was not used finger pressure was maintained on the crown until the glass ionomer cement was set.
Study: NCT05165108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagal Nerve Stimulator
Description: A handheld device which consists of a battery powered portable stimulator with a digital control user interface that controls signal amplitude and two steel contact electrodes will deliver the nVNS electrical stimulation to the cervical Vagus nerve. The device has been approved by the U.S. Food and Drug Administration (FDA) for non-invasive Vagus nerve stimulator therapy for adjunctive use for the prevention and treatment of migraine and cluster headaches in adult patients.
Study: NCT06511791

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FE 999302
Description: Effect on parameters influencing pregnancy rates when administered during different time intervals in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FE 999302
Description: Effect on parameters influencing pregnancy rates when administered during different time intervals in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FE 999302
Description: Effect on parameters influencing pregnancy rates when administered during different time intervals in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin delta
Description: The effect on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin delta
Description: The effect on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Follitropin delta
Description: The effect on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin delta
Description: The effect on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo FE 999302
Description: No active ingredient, subcutaneous injection.
Study: NCT04974957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701；BP102
Description: Drug: SHR-1701 IV infusion~Drug: BP102 IV infusion
Study: NCT04356924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological treatment
Description: The treatment is an adjusted (to the cognitively impaired individual) combination of CBT, ACT, validation strategies, and psychoeducation. One focus is to increase motivation to lifestyle changes, and to a larger degree live life in correspondence with internal goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: Computer based training tasks implemented with adaptive intensity. The cognitive training method that will be used is mainly related to executive control (i.e., ability to coordinate thoughts and actions in accordance with internal goals).
Study: NCT06511791

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo FE 999302
Description: No active ingredient, subcutaneous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo FE 999302
Description: No active ingredient, subcutaneous injection.
Study: NCT06411249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab (GSK1550188)
Description: GSK1550188 will be administered subcutaneously.
Study: NCT06559826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Following screening and baseline assessments, individuals randomized to KAP will undergo a preparatory session prior to the first day of dosing. Participants will complete a sequence of four to five intramuscular (IM) ketamine assisted therapy sessions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Following screening and baseline assessments, individuals randomized to KAP will undergo a preparatory session prior to the first day of dosing. Participants will complete a sequence of four to five intramuscular (IM) ketamine assisted therapy sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Each week following KAP, there will be a separate 60-minute integration session 1-6 days afterwards. Integration sessions will focus on processing experiences and material that emerged in KAP sessions (such as assimilating challenging experiences, making meaning of experiences and imagery, working through memories and emotions, and exploring emerging relational patterns) as well as strengthening insights. Within one week of the completion of all KAP sessions, there will be one additional integration session focused on consolidating the insights and improvements gained from KAP treatment.
Study: NCT06382636

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: This group will utilize standard care with respect to healthcare provider practices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Obstetric Prenatal Genetic Testing Engagement Solution (OPUS) AI Chatbot
Description: This group will be exposed to the AI enabled healthcare chatbot.
Study: NCT05374798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability-Biofeedback (HRV-B) via Smartwatch Device Intervention
Description: Participants will wear activity trackers equipped with continuous ambulatory physiological monitoring and geolocation. Ecological momentary assessment (EMA; 4 times daily plus optional event-triggered reports) of alcohol use, couple conflict including IPV, and affect will be completed via smartphone application for 28 days. During days 21-28, participants will also be prompted to complete a 10 minute self-administered HRV-B session at least once daily. Subjective usability, feasibility, and acceptability of HRV-B will be assessed. HRV-B will guide participants in an evidence-based paced breathing technique (about 6 breaths per minutes) using visualization on thier mobile device of thier real-time respiratory and cardiac parameters.~During days 21-28, participants will also be prompted to complete a 10 minute self-administered HRV-B session at least once daily. Subjective usability, feasibility, and acceptability of HRV-B will be assessed.
Study: NCT06521814

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: REFLECT scoliosis correction system
Description: (i.e. purpose of research) The Globus Reflect scoliosis correction system aims to provide curve correction for scoliosis patients who are still actively growing. Surgical correction is accomplished without spinal fusion, instead utilizing anterior vertebral body tethering. Reflect holds the convexity of the curve in place so that the concavity can grow, thereby harnessing the power of normal spine growth to correct the deformity.
Study: NCT04755153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice Facilitation
Description: Tailored interventions provided by a trained Practice Facilitator

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Practice Facilitation
Description: Implementation support without using Practice Facilitation
Study: NCT05840159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline is a synthetic tetracycline derivative with similar antimicrobial activity.
Study: NCT05798819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-010
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: IV infusion
Study: NCT05840159

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Doxycycline is a synthetic tetracycline derivative with similar antimicrobial activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline is a synthetic tetracycline derivative with similar antimicrobial activity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Doxycycline is a synthetic tetracycline derivative with similar antimicrobial activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT05890495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine topical
Description: 4% aqueous solution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tampon
Description: Tampon with plastic applicator provided

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Tampon
Description: Tampon with plastic applicator provided
Study: NCT05358470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy and adapted physical activity-based program
Description: Exercise therapy and adapted physical activity program based on racket sports
Study: NCT05792696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PPI guided strategies
Description: For targeted MAP or lower, if PPI\<1, more fluid therapy. if PPI\>3, vasoconstriction therapy. For MAP\<65mmHg and 1\<=PPI\<3, test bolus of 250 ml crystalloid fluid.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Empirical strategies
Description: Fluid therapy or vasoconstriction depended on experiences of anesthetic staffs.
Study: NCT05422625

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTNS Treatment
Description: Patients will be placed in a comfortable position, sitting or supine. The treatment leg will be propped up comfortably on a footrest but draped and out of view from the patient. A 34-gauge needle electrode will be inserted at a 60-degree angle 5 cm cephalad to the medial malleolus and slightly posterior to the tibia. A PTNS surface electrode will be placed on the ipsilateral calcaneus as well as 2 inactive sham surface electrodes, 1 under the little toe and 1 on the top of the foot. When the PTNS lead set is connected to the Urgent PC stimulator, a current level of 0.5 to 9 mA at 20 Hz is selected based on each patient's foot and plantar motor and sensory responses. Treatment lasts 30 minutes and given once weekly for 12 consecutive weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham PTNS Treatment
Description: Patients will be positioned similarly as PTNS patients. A Streitberger needle will be used at the tibial nerve insertion site as described above to simulate needle placement. Three electrodes will be placed on the patient's foot, two active TENS electrodes and one inactive TENS electrode. The TENS grounding pad will be a gel electrode pad from a TENS unit device that is placed on the bottom of the foot just below the smallest toe. Another gel electrode will be placed on the top of the foot just above the small toe for conduction. These two electrodes will be connected to the TENS unit lead wires for sham stimulation. A third, inactive, gel electrode, will be placed near the medial aspect of the calcaneus to mimic the PTNS treatment. The TENS electrode will be connected by lead wires to the TENS unit set at 20 HZ. The TENS unit will be turned on and stimulation slowly increased to the patient's first sensory level and then turned off.
Study: NCT05241028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: Ensartinib 225mg oral daily for 3 years or until recurrence of the disease or intolerable toxicity
Study: NCT05519319

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFA
Description: RFA will be performed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PDT
Description: PDT will be performed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFA combined with PDT
Description: RFA and PDT will be performed
Study: NCT05798819

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bevacizumab
Description: IV infusion
Study: NCT05412836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AqueousJoint
Description: AqueousJoint is a liposomal boundary lubricant, which coats the cartilage surface and protects it from further damage and degradation.